文献速递炎症性肠病

钙调神经磷酸酶抑制剂诱导后维得利珠单抗维持治疗难治性溃疡性结肠炎71例的疗效与安全性

Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-12-25

该回顾性观察研究纳入71例重度激素难治性溃疡性结肠炎患者,先以钙调神经磷酸酶抑制剂(CNI)诱导,后转为维得利珠单抗维持。中位随访25个月,3个月、1年、2年无结肠切除生存率分别为93%、67%、55%;第14周50%患者达临床缓解,62%患者CRP正常;44%患者维得利珠单抗剂量升级,未记录严重不良事件。

要点

  • CNI诱导后维得利珠单抗维持可有效降低重度激素难治性UC患者结肠切除风险。
  • 第14周50%患者达临床缓解,62%患者CRP正常。
  • 44%患者需将维得利珠单抗升级为每4周输注,中位升级时间5.6个月。

核心结论

  • CNI诱导缓解后转为维得利珠单抗维持治疗对重度激素难治性UC有效且安全。

主要发现

  • 中位随访25个月(IQR 16-36),自维得利珠单抗起始的无结肠切除生存率3个月为93%、1年为67%、2年为55%。
  • 第14周50%患者达临床缓解,62%患者CRP正常。
  • 维得利珠单抗起始后1年和2年仍用药的患者比例分别为43%和28%。
  • 44%患者维得利珠单抗剂量升级为每4周输注,中位升级时间5.6个月(IQR 4.1-8.2)。
  • 未记录严重不良事件。

临床怎么用

  • 对于CNI诱导成功的重度激素难治性UC患者,可考虑维得利珠单抗作为维持治疗选项。
  • 维持治疗中需关注部分患者需剂量升级,本研究中44%患者升级为每4周输注。

局限性

  • 回顾性观察设计,样本量有限(71例),可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Following induction therapy with a calcineurin inhibitor (CNI) in severe ulcerative colitis, transitioning to vedolizumab as maintenance therapy could be an option. AIM: To report on the largest cohort of patients successfully induced with CNIs who were transitioned to vedolizumab maintenance therapy. METHODS: This is a retrospective observational study of adult patients with severe steroid-refractory ulcerative colitis. Patients were included if they were induced with a CNI followed by maintenance therapy with vedolizumab between January 2014 and December 2018. The primary endpoint was colectomy-free survival. Secondary endpoints included survival without vedolizumab discontinuation as well as clinical, steroid-free and biochemical remission at week 14. RESULTS: A total of 71 patients (59% male) were treated with vedolizumab after induction therapy with CNIs for severe steroid-refractory colitis. Patients were followed for a median time of 25 months (IQR 16-36). Colectomy-free survival rates from vedolizumab initiation were 93% at 3 months, 67% at 1 year and 55% at 2 years. At the end of induction with vedolizumab at week 14, 50% of patients were in clinical remission, and 62% of patients had a normal CRP. At 1 and 2 years following vedolizumab initiation, 43% and 28% of patients were still on vedolizumab respectively. Vedolizumab was dose escalated to infusions every 4 weeks in 44% of patients. The median time to dose escalation was 5.6 months (IQR 4.1-8.2). No serious adverse events were recorded in our patient cohort. CONCLUSIONS: Transitioning to vedolizumab following induction of remission with CNIs is effective and safe.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 31875986. doi:10.1111/apt.15616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。